Prognostic models are investigated for advanced melanoma patients treated with targeted therapy. This study aims to identify the relationship between DMFI and outcome of 1st line targeted therapy in BRAF mutant (BRAFmut) patients.
BRAFmut patients identified from 2 referral centres were assigned to 3 prognostic groups: A (PS 0, Metastatic sites ≤3, LDH normal, CNS not involved), B (PS 1, Metastatic sites ≤3, LDH >1-2ULN, CNS not involved), C (PS 2, Metastatic sites >3, LDH ≥2ULN, CNS involved or not). Factors analysed: Distant Metastasis Free Interval (DMFI from primary melanoma to 1st distant metastasis), Post Relapse Progression Free Survival (PRPFS post relapse to BRAFi), Post Relapse Survival (PRS), number of metastatic sites, LDH, CNS involvement, PS. Univariate and multivariate Cox regression analysis was used adjusted with the 3 prognostic groups. Statistical analysis with STATA/SE V13.0.
From 380 advanced melanoma patients, 161 BRAFmut patients received 1st line BRAFi only (101) or BRAFi+MEKi (60). Patients relapsed from primary at a median DMFI 12 months (range 0-185) and were included in the 3 prognostic groups (Group A 27, Group B 72, Group C 56). To study DMFI significance, we defined 2 patient groups according to DMFI: DMFI
Patients with BRAFmut advanced melanoma and DMFI
Clinical trial identification
Legal entity responsible for the study
A' Oncology Dept, Metropolitan Hospital
All authors have declared no conflicts of interest.